Advertisement
08/03/2022

Marinus launches Ztalmy

Ztalmy is the only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older.
Sandra Levy
Senior Editor
Sandra Levy profile picture
Image
ztalmy teaser

Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the debut of of Ztalmy (ganaxolone) oral suspension, CV for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older.

CDKL5 deficiency disorder is a serious and rare genetic disorder that is caused by a mutation of the cyclin‑dependent kinase‑like 5 gene, located on the X chromosome. CDD is characterized by early‑onset, difficult‑to‑control seizures and severe neuro‑developmental impairment.

“Ztalmy represents an important first for both Marinus and the CDD community and we are proud to make it available for patients by physician prescription,” said Christy Shafer, chief commercial officer of Marinus.

[Read more: FDA gives tentative nod to Zydus Cadila for generic seizure medication

Shafer added, “With our highly experienced commercial team, designated specialty pharmacy and comprehensive patient support program, we are well-prepared to bring Ztalmy to market. We look forward to engaging with healthcare providers and supporting patient access to Ztalmy as we raise awareness about CDD and this important new treatment option.”

Physicians can access important information about the prescription fulfillment process through Orsini Specialty Pharmacy, a independent specialty pharmacy focused on rare diseases and gene therapies.

As part of Marinus’ commitment to helping people who are prescribed Ztalmy receive the support they need, the company has established Ztalmy One, a comprehensive patient support program that facilitates access to treatment and provides ongoing prescription drug support and education throughout the treatment journey. This includes prescription benefit and prior authorization support, medication delivery, financial support programs for patients with no insurance, limited insurance or a gap in coverage and a co-pay savings program that helps commercially insured eligible patients pay as low as $0 per fill for a Ztalmy prescription.

Visit ZTALMY.com to learn about full program offer and terms and conditions. The support team is available Monday through Friday, 8:00 a.m. to 8:00 p.m. Eastern Time, with pharmacists available 24/7.

    Advertisement
    Advertisement